We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Journal Scan / Research · June 22, 2020

Pembrolizumab Extends Survival in Patients With Leptomeningeal Carcinomatosis

Nature Medicine


Additional Info

Nature Medicine
Single-Arm, Open-Label Phase 2 Trial of Pembrolizumab in Patients With Leptomeningeal Carcinomatosis
Nat. Med. 2020 Jun 02;[EPub Ahead of Print], PK Brastianos, EQ Lee, JV Cohen, SM Tolaney, NU Lin, N Wang, U Chukwueke, MD White, N Nayyar, A Kim, C Alvarez-Breckenridge, I Krop, MK Mahar, MS Bertalan, B Shaw, JL Mora, N Goss, M Subramanian, L Nayak, J Dietrich, DA Forst, BV Nahed, TT Batchelor, HA Shih, ER Gerstner, B Moy, D Lawrence, A Giobbie-Hurder, SL Carter, K Oh, DP Cahill, RJ Sullivan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading